Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
View Patent ↗Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide.
1. A method for increasing Bag5 expression in an individual comprising:
identifying an individual having a decreased expression level of Bag5 in a neuronal tissue; and
administering to the individual, identified as having the decreased expression level of Bag5 in the neuronal tissue, an effective amount of a nitroxide antioxidant, wherein the nitroxide antioxidant is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl,
whereby the expression level of Bag5 is increased.
2. The method of claim 1 , wherein the individual is over the age of 35.
3. The method of claim 1 , wherein the individual is over the age of 55.
4. The method of claim 1 , whereby the expression level of Bag5 is increased in a neuronal tissue.
5. The method of claim 1 , wherein the decreased expression level of Bag5 is age-related.
6. The method of claim 1 , wherein the decreased expression level of Bag5 is disease-related.
7. A method for increasing Bag5 expression in an individual in need thereof, comprising:
administering to an individual an effective amount of a nitroxide antioxidant,
wherein the individual is known to have a decreased expression level of Bag5, and
wherein the nitroxide antioxidant is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl,
whereby the expression level of Bag5 is increased.
8. The method of claim 7 , wherein the individual is over the age of 35.
9. The method of claim 7 , wherein the individual is over the age of 55.
10. The method of claim 7 , wherein the decreased expression level of Bag5 is age-related.
11. The method of claim 7 , wherein the decreased expression level of Bag5 is disease-related.
12. The method of claim 7 , wherein the individual is known to have a decreased expression level of Bag5 in a connective tissue, a muscle tissue, a neuronal tissue, a nervous tissue, an epithelial tissue, a skin tissue an adipose tissue, an immune tissue, a pancreatic tissue, blood or a combination thereof.
13. The method of claim 7 , whereby the expression level of Bag5 is increased in a connective tissue, a muscle tissue, a neuronal tissue, a nervous tissue, an epithelial tissue, a skin tissue, an adipose tissue, an immune tissue, a pancreatic tissue, blood or a combination thereof.
14. A method comprising:
identifying an individual having a decreased expression level of Bag5; and
administering to the individual an effective amount of a nitroxide antioxidant, wherein the nitroxide antioxidant is 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl,
whereby the expression level of Bag5 is increased.
15. The method of claim 14 , wherein the individual is over the age of 35.
16. The method of claim 14 , wherein the individual is over the age of 55.
17. The method of claim 14 , wherein the decreased expression level of Bag5 is age-related.
18. The method of claim 14 , wherein the decreased expression level of Bag5 is disease-related.
19. The method of claim 14 , wherein the individual is identified as having a decreased expression level of Bag5 in a connective tissue, a muscle tissue, a neuronal tissue, a nervous tissue, an epithelial tissue, a skin tissue, an adipose tissue, an immune tissue, a pancreatic tissue, blood or a combination thereof.
20. The method of claim 14 , whereby the expression level of Bag5 is increased in a connective tissue, a muscle tissue, a neuronal tissue, a nervous tissue, an epithelial tissue, a skin tissue, an adipose tissue, an immune tissue, a pancreatic tissue, blood or a combination thereof.